Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, ...
"The results from RESONATE-2 continue to reaffirm the clinical benefit of ibrutinib and signal its potential to treat CLL patients in earlier lines of therapy, serving as an alternative to the current ...
Despite the complexities associated with treating older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), patients in the RESONATE-2 trial continue to ...
The FINANCIAL — On December 6, AbbVie announced the results of RESONATE-2 (PCYC-1115), a Phase 3 clinical trial in which ibrutinib (IMBRUVICA) significantly decreased the risk of progression or death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback